Bharat Biotech again applies for vaccine's emergency approval
Published By : Prameya News Bureau | December 23, 2020 IST
Share
New Delhi, Dec 23: Hyderabad-based Bharat Biotech, which is developing the country's indigenous coronavirus vaccine in collaboration with the Indian Council of Medical Research, on Wednesday again applied to the Drug Controller General of India for the emergency use authorisation. "The company applied for the emergency use authorisation in the evening," a company source told IANS. Emergency Use Authorisation is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies. Bharat Biotech had first applied for the emergency use authorisation of its vaccine on December 7 and presented its proposal, along with the interim safety and immunogenicity data of Phase 1 and 2 clinical trials. The Central Drugs Standard Control Organisation's (CDSCO) expert panel had, however, recommended that the firm should present the safety and efficacy data from the ongoing Phase 3 clinical trial in the country for further consideration. Bharat Biotech's COVAXIN, an inactivated vaccine candidate, is currently undergoing Phase 3human clinical trials on 26,000 volunteers over 25 centres across India, after having undergone Phase 1 and 2 trials involving 1,000 volunteers. Meanwhile, the Serum Institute of India (SII) has also submitted the additional data asked by the DCGI determining safety and immunogenicity of its COVID-19 vaccine candidate, Covishield. America's Pfizer was the first to apply on December 4, followed by Pune-based SII and Bharat Biotech who applied on December 6 and 7, respectively. Pfizer had, however, requested more time to make presentation before the committee. Pfizer, whose vaccine has been authorized in the US, the UK and Canada, has written to DCGI seeking a fresh date to present its case for the EUA of their vaccine candidate BNT162b2, after it failed to present its data before the vaccine reviewing committee of the CDSCO earlier. India is likely to have a Covid-19 vaccine approved for emergency use before December end as CDSCO's expert panel is set to review the application of SII, Bharat Biotech and Pfizer for emergency use authorisation. (IANS)
News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
PM Modi lambasts Congress, says Rajiv Gandhi abolished inheritance law to 'save own interests'
Telangana CM Revant Reddy alleges conspiracy to stop reservations in the country
EC sends notice to BJP over MCC violation by PM Modi
Lok Sabha polls: ECI takes cognizance of MCC violations by Rahul Gandhi
PM Modi accuses Congress of "tying hands of soldiers", says we have given full freedom to retaliate
Lok Sabha polls: NCP(SP)’s manifesto promises Rs 1 lakh/year dole to poor women & jobless youth
JDU youth leader shot dead in Bihar’s Patna
Lok Sabha polls: PM Modi to campaign in MP, UP today
Karnataka's Election Commission plans 1,832 special polling booths for inclusive voting
Bridge connecting to Manipur damaged by IED blasts
BRS chief KCR starts 17-day bus yatra to boost party campaign ahead of polls
All three units of EVMs have their own microcontroller: SC informed
India to become one of biggest semiconductor hubs in next 5 years: Vaishnaw
PM Modi advocates for resilient infrastructure at 39-nation meet on natural disasters
Supreme Court to issue directions on mandatory VVPAT verification
PM Modi to address public meetings in Chhattisgarh, MP today
DRDO develops India's lightest bulletproof jacket
Lok Sabha polls: NDA will sweep all 28 seats in K'taka, says Amit Shah
India carries out successful launch of medium-range ballistic missile's new version